PMID- 33413449
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20240330
IS  - 1743-422X (Electronic)
IS  - 1743-422X (Linking)
VI  - 18
IP  - 1
DP  - 2021 Jan 7
TI  - Higher expression of monocyte chemotactic protein 1 in mild COVID-19 patients 
      might be correlated with inhibition of Type I IFN signaling.
PG  - 12
LID - 10.1186/s12985-020-01478-9 [doi]
LID - 12
AB  - BACKGROUND: Chemokine levels in severe coronavirus disease 2019 (COVID-19) 
      patients have been shown to be markedly elevated. But the role of chemokines in 
      mild COVID-19 has not yet been established. According to the epidemiological 
      statistics, most of the COVID-19 cases in Shiyan City, China, have been mild. The 
      purpose of this study was to evaluate the level of chemokines in mild COVID-19 
      patients and explore the correlation between chemokines and host immune response. 
      METHODS: In this study, we used an enzyme-linked immunosorbent assay to detect 
      serum levels of chemokines in COVID-19 patients in Shiyan City. Expression of 
      chemokine receptors and of other signaling molecules was measured by real-time 
      polymerase chain reaction. RESULTS: We first demonstrated that COVID-19 patients, 
      both sever and mild cases, are characterized by higher level of chemokines. 
      Specifically, monocyte chemotactic protein 1 (MCP-1) is expressed at higher 
      levels both in severe and mild cases of COVID-19. The receptor of MCP-1, C-C 
      chemokine receptor type 2, was expressed at higher levels in mild COVID-19 
      patients. Finally, we observed a significant negative correlation between 
      expression levels of interferon (IFN) regulatory factor 3 (IRF3) and serum levels 
      of MCP-1 in mild COVID-19 patients. CONCLUSION: Higher expression of MCP-1 in 
      mild COVID-19 patients might be correlated with inhibition of IFN signaling. The 
      finding adds to our understanding of the immunopathological mechanisms of severe 
      acute respiratory syndrome coronavirus 2 infection and provides potential 
      therapeutic targets and strategies.
FAU - Xi, Xueyan
AU  - Xi X
AUID- ORCID: 0000-0002-3164-9895
AD  - Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, No. 30 
      Renmin Nanlu, Shiyan City, Hubei Province, 442000, People's Republic of China. 
      xixueyan2001@126.com.
AD  - Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of 
      Medicine, Shiyan City, People's Republic of China. xixueyan2001@126.com.
AD  - Renmin Hospital, Hubei University of Medicine, Shiyan City, People's Republic of 
      China. xixueyan2001@126.com.
FAU - Guo, Yang
AU  - Guo Y
AD  - Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, No. 30 
      Renmin Nanlu, Shiyan City, Hubei Province, 442000, People's Republic of China.
AD  - Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of 
      Medicine, Shiyan City, People's Republic of China.
FAU - Zhu, Min
AU  - Zhu M
AD  - Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, No. 30 
      Renmin Nanlu, Shiyan City, Hubei Province, 442000, People's Republic of China.
FAU - Wei, Yuhui
AU  - Wei Y
AD  - Institute of Neuroscience, Hubei University of Medicine, Shiyan City, People's 
      Republic of China.
FAU - Li, Gang
AU  - Li G
AD  - Renmin Hospital, Hubei University of Medicine, Shiyan City, People's Republic of 
      China.
FAU - Du, Boyu
AU  - Du B
AD  - Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, No. 30 
      Renmin Nanlu, Shiyan City, Hubei Province, 442000, People's Republic of China.
FAU - Wang, Yunfu
AU  - Wang Y
AD  - Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, No. 30 
      Renmin Nanlu, Shiyan City, Hubei Province, 442000, People's Republic of China. 
      wyfymc@sina.com.
AD  - Institute of Neuroscience, Hubei University of Medicine, Shiyan City, People's 
      Republic of China. wyfymc@sina.com.
LA  - eng
GR  - 20Y01/Emergency Research Project for COVID-19 of Shiyan City/International
GR  - 2020XGFYZR02/Emergency Research Project for COVID-19 of Hubei University of 
      Medicine/International
GR  - 2020XGFYZR03/Emergency Research Project for COVID-19 of Hubei University of 
      Medicine/International
GR  - HBMUPI201804/The Principal Grant of Hubei University of Medicine/International
GR  - 2017CFB238/Hubei Provincial Natural Science Foundation/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210107
PL  - England
TA  - Virol J
JT  - Virology journal
JID - 101231645
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokines)
RN  - 0 (IRF3 protein, human)
RN  - 0 (Interferon Regulatory Factor-3)
RN  - 0 (Interferon Type I)
RN  - 0 (Receptors, CCR2)
SB  - IM
MH  - Adult
MH  - COVID-19/*immunology/metabolism/physiopathology
MH  - Chemokine CCL2/*blood
MH  - Chemokines/*blood
MH  - China
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Interferon Regulatory Factor-3/blood
MH  - Interferon Type I/*metabolism
MH  - Leukocytes, Mononuclear/metabolism
MH  - Male
MH  - Middle Aged
MH  - Receptors, CCR2/blood
MH  - Signal Transduction/immunology
PMC - PMC7788192
OTO - NOTNLM
OT  - COVID-19
OT  - Chemokines
OT  - IFN signaling
OT  - MCP-1
OT  - Mild
COIS- The authors declare that they have no competing interests.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/28 06:00
PMCR- 2021/01/07
CRDT- 2021/01/08 05:45
PHST- 2020/09/08 00:00 [received]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/01/08 05:45 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
PHST- 2021/01/07 00:00 [pmc-release]
AID - 10.1186/s12985-020-01478-9 [pii]
AID - 1478 [pii]
AID - 10.1186/s12985-020-01478-9 [doi]
PST - epublish
SO  - Virol J. 2021 Jan 7;18(1):12. doi: 10.1186/s12985-020-01478-9.